Sponsored by
Experts at the University of Michigan are investigating a two-pronged attack for treating high grade glioma. Their Phase 1 first-in-human trial tested two adenoviral vectors (HSV1-TK and Flt3L) injected directly into the tumor bed after resection. Of the 18 patients enrolled, 14 had gbm, three had gliosarcoma, and one had anaplastic ependymoma. The treatment was well-tolerated, and median OS was 21.3 months. The 2-year survival rate was 40%, with seven patients living beyond two years, three patients beyond three years, and one still living 60 months after enrollment. Study investigators believe this treatment approach may be even more effective for IDH1-mutated patients. We'll be doing a webinar on this exciting new treatment on May 16 (see above)!